Use of ReliZORB for Feeding Intolerance in Critically Ill Patients

The purpose of this study is to determine if the use of ReliZORB improves nutrition tolerance and helps critically ill patients meet their nutrition goals. Subjects in the intensive care unit will be enrolled and randomized 2:1 to receive ReliZORB or placebo cartridges with enteral feedings for 5 days. Blood and stool samples will be collected to test for nutrition and inflammation.

Inclusion Criteria:Admission to Surgical or Medical Intensive Care Unit within 72 hoursEvidence of multi-organ failureNo enteral nutrition startedExclusion Criteria:Pregnant women and prisonersHypotension is attributed to suspected or confirmed cardiogenic shockMoribund patients (expected to pass within 72h)Evidence of intestinal obstruction, ischemia, bleeding, perforation, fistulas or tract discontinuitySepsis suspected or confirmed due to an abdominal sourceC. Difficile or other gastrointestinal infection that may manifest with diarrheaConstipation as a pre-existing comorbidityUse of pancreatic hormone stimulant or inhibitor during or immediately prior to hospital admissionUse of parenteral nutritionPatients receiving cancer-related treatment in the last 6 months